[{"id":"9d2b54f0-0907-4b8a-b5db-69cd00d54eb2","acronym":"SWOG S1608","url":"https://clinicaltrials.gov/study/NCT03269669","created_at":"2021-01-29T07:15:29.475Z","updated_at":"2025-02-25T12:26:46.064Z","phase":"Phase 2","brief_title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","source_id_and_acronym":"NCT03269669 - SWOG S1608","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/23/2018","start_date":" 01/23/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"8de268c6-da6c-4e99-84fd-668feff0456e","acronym":"ALLIANCE A041202","url":"https://clinicaltrials.gov/study/NCT01886872","created_at":"2021-01-17T17:18:59.159Z","updated_at":"2024-07-02T16:34:37.292Z","phase":"Phase 3","brief_title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01886872 - ALLIANCE A041202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 08/07/2018","primary_completion_date":" 08/07/2018","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-07"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"adf70f50-0fc0-4474-a764-ea766f835694","acronym":"","url":"https://clinicaltrials.gov/study/NCT01286272","created_at":"2021-01-18T05:13:11.418Z","updated_at":"2024-07-02T16:35:02.742Z","phase":"Phase 2","brief_title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01286272","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":"","alterations":" ","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 04/08/2011","start_date":" 04/08/2011","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-05-17"},{"id":"b73496d5-e698-47e5-b7a2-1ea85e0d187e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696784","created_at":"2021-01-18T18:07:07.182Z","updated_at":"2024-07-02T16:35:07.400Z","phase":"Phase 1","brief_title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","source_id_and_acronym":"NCT03696784","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-26"},{"id":"2b050358-3cb8-4957-b9a8-e85ed3d13514","acronym":"","url":"https://clinicaltrials.gov/study/NCT04083495","created_at":"2021-01-18T19:59:38.796Z","updated_at":"2024-07-02T16:35:08.223Z","phase":"Phase 2","brief_title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","source_id_and_acronym":"NCT04083495","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 02/23/2028","primary_completion_date":" 02/23/2028","study_txt":" Completion: 08/01/2038","study_completion_date":" 08/01/2038","last_update_posted":"2024-04-23"},{"id":"9c9271f5-1a7e-4c0e-a836-6adeffa127dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04223765","created_at":"2021-04-23T04:56:25.788Z","updated_at":"2024-07-02T16:35:08.115Z","phase":"Phase 1","brief_title":"Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","source_id_and_acronym":"NCT04223765","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-23"},{"id":"55894086-9f15-41f3-85e1-c28965784c6c","acronym":"CLL2-BZAG","url":"https://clinicaltrials.gov/study/NCT04515238","created_at":"2021-01-18T21:38:16.392Z","updated_at":"2024-07-02T16:35:13.069Z","phase":"Phase 2","brief_title":"Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL","source_id_and_acronym":"NCT04515238 - CLL2-BZAG","lead_sponsor":"German CLL Study Group","biomarkers":" BCL2 • PLCG2","pipe":"","alterations":" ","tags":["BCL2 • PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-03-25"},{"id":"b7e05237-c123-498d-b356-0eff2ae8d36b","acronym":"ACE-LY-308","url":"https://clinicaltrials.gov/study/NCT02972840","created_at":"2021-01-18T14:36:50.624Z","updated_at":"2024-07-02T16:35:15.640Z","phase":"Phase 3","brief_title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","source_id_and_acronym":"NCT02972840 - ACE-LY-308","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 635","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 10/28/2025","primary_completion_date":" 10/28/2025","study_txt":" Completion: 10/28/2025","study_completion_date":" 10/28/2025","last_update_posted":"2024-03-08"},{"id":"60e63980-bc0c-401e-a0fc-6fabe46bb034","acronym":"","url":"https://clinicaltrials.gov/study/NCT03623373","created_at":"2021-01-18T17:48:07.465Z","updated_at":"2025-02-25T15:07:50.049Z","phase":"Phase 2","brief_title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT03623373","lead_sponsor":"Washington University School of Medicine","biomarkers":" CCND1 • CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 02/09/2020","primary_completion_date":" 02/09/2020","study_txt":" Completion: 02/05/2025","study_completion_date":" 02/05/2025","last_update_posted":"2024-02-13"},{"id":"5fef4db7-7b60-44eb-a4dd-40058c1475c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04587687","created_at":"2021-01-18T21:53:04.529Z","updated_at":"2024-07-02T16:35:22.744Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04587687","lead_sponsor":"Joseph Tuscano","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • bendamustine • Belrapzo (bendamustine RTD)"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-01-22"},{"id":"bb01e540-077e-40c1-931c-07315b7ce5c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04115631","created_at":"2021-01-18T20:07:06.177Z","updated_at":"2024-07-02T16:35:45.128Z","phase":"Phase 2","brief_title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT04115631","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" CCND1 • CD34","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 12/13/2019","start_date":" 12/13/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-06-22"},{"id":"5a039bc9-39b0-4a4e-8bec-0be78978180e","acronym":"CHARIOT","url":"https://clinicaltrials.gov/study/NCT04268706","created_at":"2021-01-18T20:44:27.947Z","updated_at":"2024-07-02T16:35:51.430Z","phase":"Phase 2","brief_title":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","source_id_and_acronym":"NCT04268706 - CHARIOT","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Belrapzo (bendamustine RTD) • TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2023-04-05"},{"id":"ca9a24a9-fca8-4fdc-9ecd-ef5a847c7a80","acronym":"CITADEL-310","url":"https://clinicaltrials.gov/study/NCT04849715","created_at":"2021-04-19T11:53:03.799Z","updated_at":"2024-07-02T16:36:11.219Z","phase":"Phase 3","brief_title":"A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT04849715 - CITADEL-310","lead_sponsor":"Incyte Corporation","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • parsaclisib (INCB50465) • Belrapzo (bendamustine RTD)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 08/15/2030","primary_completion_date":" 08/15/2030","study_txt":" Completion: 07/07/2034","study_completion_date":" 07/07/2034","last_update_posted":"2022-04-29"},{"id":"49925289-fb2e-43b6-8ef3-a1145df84116","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914885","created_at":"2021-01-18T19:16:35.512Z","updated_at":"2024-07-02T16:36:19.889Z","phase":"","brief_title":"Compassionate Use Re-Infusion of ATLCAR.CD30","source_id_and_acronym":"NCT03914885","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-12-03"}]